Needham & Company Reaffirms Buy Rating for Establishment Labs

Investment firm Needham & Company LLC has reaffirmed its “buy” rating for Establishment Labs (NASDAQ: ESTA), according to a note issued to investors on Monday. The firm has set a price target of $84.00 for the stock, indicating a potential upside of 26.39% from its previous close.

Other research firms have also recently weighed in on the stock. Citigroup raised its price target from $62.00 to $75.00 with a “neutral” rating, while Mizuho increased its price objective from $85.00 to $90.00 and maintained an “outperform” rating. In a report dated October 19, Wall Street Zen upgraded Establishment Labs from a “sell” to a “hold” rating. Additionally, BTIG Research raised their price objective from $81.00 to $86.00 and reiterated a “buy” rating on December 31. Meanwhile, JPMorgan Chase & Co. increased its target price from $71.00 to $80.00 and assigned an “overweight” rating in a report on December 17.

The consensus among research analysts indicates a “Moderate Buy” rating, with an average price target of $78.86 based on data from MarketBeat. Currently, six analysts recommend buying the stock, one suggests holding, and one advises selling.

Recent Financial Performance

Establishment Labs reported its quarterly earnings on November 5, revealing a loss of $0.38 per share for the quarter. This figure surpassed analysts’ consensus estimates of $0.54 by $0.16. The company achieved revenues of $53.78 million, exceeding the expected $52.28 million. This represents a year-over-year revenue growth of 33.8%, compared to the same quarter last year when the company reported a loss of $0.59 per share.

Despite the positive revenue growth, Establishment Labs recorded a negative return on equity of 235.45% and a net margin of 43.45%. Analysts predict earnings per share for the current fiscal year will be approximately -2.41.

Institutional Investors Take Notice

The investment landscape for Establishment Labs has seen significant activity from institutional investors. In particular, CenterBook Partners LP acquired a new position in the second quarter valued at $16.2 million. Similarly, Viking Global Investors LP purchased shares worth $14.67 million during the same period.

Bamco Inc. NY increased its holdings by 30.2% in the third quarter, now owning 1,181,824 shares valued at $48.44 million after acquiring an additional 274,287 shares. Woodson Capital Management LP also boosted its position by 113.3%, owning 480,000 shares valued at $19.68 million after adding 255,000 shares. Currently, institutional investors hold 72.91% of Establishment Labs’ stock.

Establishment Labs Holdings Inc. is recognized as a global medical technology company that specializes in the design, development, and manufacturing of silicone gel breast implants for both aesthetic and reconstructive surgeries. Its proprietary products focus on patient safety, customization, and innovation, enhancing surgical outcomes and ensuring clinical traceability. Notably, the company’s flagship products are marketed under the Motiva® brand, which features ergonomic and round breast implants, equipped with SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

As the company navigates the complexities of the medical technology market, the reaffirmation of its “buy” rating by Needham & Company LLC highlights ongoing investor confidence in Establishment Labs.